UK pharma investment shows 'green shoots' with £2bn committed, but delivery will decide recovery

The UK has begun to reverse years of decline as a destination for global pharmaceutical investment, with the industry committing an additional £2 billion since September 2025, according to the Association of the British Pharmaceutical Industry's (ABPI (搜索)搜索该词条) 2026 flagship Competitiveness Report. The investments span the value chain, from AI-enabled discovery science to large-scale medicines manufacturing, and have been made possible through collaboration between industry and government alongside a combination of short- and long-term policy commitments.

Richard Torbett, ABPI (搜索)搜索该词条 Chief Executive, said: "A year ago, the UK was losing ground in the global race for pharmaceutical investment. Today, the picture is more hopeful. Through a real partnership between government and industry, we have started to turn a trend of disinvestment into one of green shoots, with £2 billion of new investment committed over the past year alone. But this recovery is not yet secure."

Torbett added: "Investors make decisions that play out over decades, and they are watching closely to see whether the UK delivers on the commitments it has made. The task now is to provide and proceed along a clear, reliable roadmap to delivery so companies can invest with confidence. Get this right, and the UK can unlock tens of thousands of high-value jobs, billions of pounds of growth, and faster access to new medicines for NHS patients."

Policy commitments driving renewed confidence

The recovery has been underpinned by several policy measures, including an increase to the baseline cost-benefit threshold used by the National Institute for Health and Care Excellence (NICE) and a commitment to increase UK investment in innovative medicines to 0.6% of GDP. Raising NICE's threshold to £25,000–35,000 per QALY — the first increase since the early 2000s — has already enabled nine additional medicines to be approved for use in England and Wales between April and June 2026, which would have been denied to patients had the threshold not been raised.

The government has also capped the clawback rate for newer branded medicines at 15%, a move that coincided with the newer medicines rate falling to 14.5% in 2026 from a 2025 peak of 22.9%. Despite this improvement, the UK's clawback rate remains higher than every other comparator country in the analysis, several of which operate no clawback system at all.

The economic prize at stake

The pharmaceutical industry already supports more than 125,000 jobs across every UK nation and region. If investment and growth accelerate, the sector could create as many as 81,300 new jobs by 2035, expanding the pharmaceutical workforce to around 200,000 people and generating £33.4 billion of direct Gross Value Added each year, up from £20.4 billion today.

Competitive strengths under pressure

The report benchmarks the UK's attractiveness against 12 leading pharmaceutical markets using more than 40 international metrics. The UK retains core competitive strengths, but several are at risk of erosion. The UK ranks in the top three for seven of nine science-base metrics, more than any other country, with 16 of the world's top 100 universities for life sciences, the largest government health R&D budget in Europe, and a first-place ranking in Europe for the number of biotechs and venture capital raised.

However, the UK slipped to third in the Nature Index as China extended its lead, and its share of the world's most-cited medical publications fell to 1.8% in 2024. The proportion of UK students graduating in natural sciences, mathematics, and statistics has declined from 9.22% in 2020 to 7.97% in 2023, with the recent closure of undergraduate chemistry courses in 11 universities pointing to a thinning talent pipeline.

On intellectual property, the UK maintains ten years of Regulatory Data Protection and five-year Supplementary Protection Certificates, while the EU moves to reduce its own protections. Yet reliability is an emerging risk: recent UK court rulings on the 'doctrine of plausibility' have diverged from European courts and revoked patents upheld elsewhere.

Persistent weaknesses in medicines access and adoption

Just 33% of new medicines were made fully available for their licensed use in 2021–24, and the UK ranks last among European comparators for adoption of new, innovative medicines. The UK also sits below every comparator country for spending on innovative medicines, a long-term driver of negative investor sentiment.

Regulatory and clinical trial progress

The Medicines and Healthcare products Regulatory Agency (MHRA) has improved its performance, with the median time to approve a new medicine falling from 427 days in 2024 to 378 days in 2025, leaving the UK fourth of six agencies analysed. Nearly all (98%) clinical trial applications now receive regulatory approval within 60 days.

However, clinical trial delivery remains a concern. Only 58% of industry trials opened to recruitment within 60 days of approval, and recruitment to interventional industry clinical trials fell by 25% between 2022/23 and 2024/25. The new network of 35 Commercial Clinical Research Delivery Centres is outperforming the wider health system in study set-up.

Health data as a potential unique selling point

The Health Data Research Service, backed by £600 million from government and Wellcome (搜索)搜索该词条, could transform the UK's fragmented health data assets into a coherent national service and a major draw for investment. A leadership team and strategic vision are now in place, and delivery will test whether this becomes the UK's unique selling point.

Global competition intensifying

The UK faces a more complex and competitive global market. The UK can now deploy up to £570 million of capital grants over five years, a major success of the Sector Plan, though competitors are improving their own incentives. Ireland raised its R&D tax credit from 30% to 35% in January 2026, and Japan introduced a 40% credit for strategic technologies, including pharmaceuticals, in March 2026, compared to the UK's current 20% rate of R&D tax relief.